{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:21:06Z","timestamp":1790965266674,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["MP470"],"award-info":[{"award-number":["MP470"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.radonc.2020.05.051","type":"journal-article","created":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T10:52:01Z","timestamp":1591527121000},"page":"114-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy"],"prefix":"10.1016","volume":"150","author":[{"given":"Dawei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshal R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5863-6023","authenticated-orcid":false,"given":"Vivek","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishab","family":"Ramapriyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8209-6119","authenticated-orcid":false,"given":"Hampartsoum B.","family":"Barsoumian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angelica","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2020.05.051_b0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fimmu.2019.00193","article-title":"Role of radiation therapy in modulation of the tumor stroma and microenvironment","volume":"10","author":"Menon","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.radonc.2020.05.051_b0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","article-title":"A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors","volume":"123","author":"Venkatesulu","year":"2018","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.radonc.2020.05.051_b0015","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3109\/07357907.2012.700987","article-title":"The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas","volume":"30","author":"Balmanoukian","year":"2012","journal-title":"Cancer Invest"},{"key":"10.1016\/j.radonc.2020.05.051_b0020","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant","volume":"41","author":"Reynders","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2020.05.051_b0025","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ijrobp.2014.04.025","article-title":"Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes","volume":"89","author":"Tang","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.05.051_b0030","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijrobp.2015.11.026","article-title":"Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer","volume":"94","author":"Wild","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.05.051_b0035","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/07357907.2012.762780","article-title":"The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells","volume":"31","author":"Yovino","year":"2013","journal-title":"Cancer Invest"},{"key":"10.1016\/j.radonc.2020.05.051_b0050","doi-asserted-by":"crossref","first-page":"9104-","DOI":"10.1200\/JCO.2019.37.15_suppl.9104","article-title":"Randomized phase I\/II trial of pembrolizumab with and without radiotherapy for metastatic non-small cell lung cancer","volume":"37","author":"Welsh","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.05.051_b0055","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jtho.2019.10.001","article-title":"Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensive-stage small cell lung cancer","volume":"15","author":"Welsh","year":"2020","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.radonc.2020.05.051_b0060","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1158\/2326-6066.CIR-18-0793","article-title":"Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses","volume":"7","author":"Welsh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.radonc.2020.05.051_b0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","article-title":"Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines?","volume":"7","author":"Menetrier-Caux","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.radonc.2020.05.051_b0070","article-title":"Absolute lymphocyte count predicts abscopal responses and outcomes in patients receiving combined immunotherapy and radiation therapy: analysis of 3 phase 1\/2 trials","author":"Chen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.05.051_b0075","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2020.05.051_b0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jrr\/rrt080","article-title":"Significance of low-dose radiation distribution in development of radiation pneumonitis after helical-tomotherapy-based hypofractionated radiotherapy for pulmonary metastases","volume":"55","author":"Jo","year":"2014","journal-title":"J Radiat Res"},{"key":"10.1016\/j.radonc.2020.05.051_b0085","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non\u2013small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.05.051_b0090","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2020.05.051_b0095","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.adro.2018.08.003","article-title":"Toxicity of radiation and immunotherapy combinations","volume":"3","author":"Verma","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.05.051_b0100","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ijrobp.2018.04.054","article-title":"Safety of combined immunotherapy and thoracic radiation therapy: analysis of 3 single-institutional phase I\/II trials","volume":"101","author":"Verma","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.05.051_b0105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000492","article-title":"Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.radonc.2020.05.051_b0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s40425-019-0718-6","article-title":"Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy","volume":"7","author":"Menon","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.radonc.2020.05.051_b0115","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.radonc.2016.04.025","article-title":"Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation","volume":"119","author":"Tucker","year":"2016","journal-title":"Radiother Oncol"}],"updated-by":[{"DOI":"10.1016\/j.radonc.2021.01.017","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000}}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020303078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020303078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:10:20Z","timestamp":1779811820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814020303078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":21,"alternative-id":["S0167814020303078"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2020.05.051","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2020.05.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}